NASDAQ:MYL - Mylan Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.33
  • Forecasted Upside: 28.25 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$15.86
+0.30 (1.20%)
Get New Mylan Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.33
▲ +28.25% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Mylan in the last 3 months. The average price target is $20.33, with a high forecast of $27.00 and a low forecast of $16.00. The average price target represents a 28.25% upside from the last price of $15.86.
Hold
The current consensus among 7 investment analysts is to hold stock in Mylan. This rating has held steady since June 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 14 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/28/2020Wells Fargo & CompanyLower Price TargetEqual Weight$17.00 ➝ $16.00Medium
i
9/8/2020Raymond JamesReiterated RatingBuyHigh
i
8/11/2020UBS GroupBoost Price TargetNeutral$17.00 ➝ $18.00Medium
i
5/13/2020UBS GroupBoost Price TargetNeutral$16.00 ➝ $17.00High
i
5/12/2020Royal Bank of CanadaReiterated RatingBuy$26.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
4/30/2020Wells Fargo & CompanyLower Price TargetEqual Weight$23.00 ➝ $18.00Low
i
4/15/2020Piper SandlerLower Price TargetNeutral$23.00 ➝ $17.00Low
i
4/2/2020Morgan StanleyLower Price TargetEqual Weight$23.00 ➝ $18.00High
i
3/27/2020Royal Bank of CanadaLower Price TargetOutperform$27.00 ➝ $26.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
2/5/2020SunTrust BanksReiterated RatingBuy$27.00Medium
i
Rating by Gregg Gilbert at SunTrust Banks, Inc.
1/9/2020Piper SandlerInitiated CoverageNeutral$21.00Medium
i
1/6/2020Royal Bank of CanadaBoost Price TargetOutperform$25.00 ➝ $27.00High
i
12/16/2019Evercore ISIReiterated RatingBuyMedium
i
Rating by Umer Raffat at Evercore ISI
11/27/2019CfraUpgradeHoldLow
i
Rating by Colin Scarola at Cfra
11/7/2019Morgan StanleyDowngradeOverweight ➝ Equal$25.00 ➝ $18.00Low
i
Rating by David Risinger at Morgan Stanley
11/5/2019CfraDowngradeHold ➝ SellHigh
i
9/12/2019SunTrust BanksBoost Price TargetBuy$25.00 ➝ $27.00Low
i
8/9/2019Evercore ISIReiterated RatingBuyN/A
i
Rating by Umer Raffat at Evercore ISI
7/31/2019CitigroupSet Price TargetBuy$26.00Low
i
Rating by Liav Abraham at Citigroup Inc.
7/31/2019Credit Suisse GroupReiterated RatingBuy$34.50Low
i
7/30/2019MizuhoBoost Price TargetNeutral$25.00 ➝ $27.00Low
i
Rating by Irina Rivkind Koffler at Mizuho
7/30/2019Morgan StanleyReiterated RatingOverweight$22.00 ➝ $25.00Low
i
Rating by David Risinger at Morgan Stanley
7/19/2019Wolfe ResearchInitiated CoverageOutperform ➝ Outperform$27.00Low
i
7/15/2019Morgan StanleySet Price TargetBuy$22.00Low
i
Rating by David Risinger at Morgan Stanley
6/12/2019Cantor FitzgeraldLower Price TargetNeutral$31.00 ➝ $18.00Low
i
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$26.00Medium
i
5/28/2019UBS GroupLower Price TargetNeutral$23.00Low
i
5/14/2019MizuhoReiterated RatingHoldMedium
i
Rating by Irina Rivkind Koffler at Mizuho
5/8/2019Morgan StanleySet Price TargetBuy$32.00Medium
i
Rating by David Risinger at Morgan Stanley
5/8/2019Raymond JamesSet Price TargetBuy$31.00Medium
i
Rating by Elliot Wilbur at Raymond James
5/8/2019BMO Capital MarketsSet Price TargetBuy$36.00Medium
i
Rating by Gary Nachman at BMO Capital Markets
5/8/2019Royal Bank of CanadaLower Price TargetOutperform$26.00Low
i
5/7/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$33.00 ➝ $22.00Low
i
4/1/2019Cantor FitzgeraldReiterated RatingHold$41.00High
i
3/27/2019ArgusLower Price TargetBuy$32.00Medium
i
Rating by Jasper Hellweg at Argus
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$35.00Low
i
3/7/2019UBS GroupReiterated RatingNeutral$31.00Low
i
3/6/2019Credit Suisse GroupReiterated RatingBuy$37.00Low
i
3/6/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$35.00Medium
i
Rating by David Risinger at Morgan Stanley
2/27/2019Wells Fargo & CompanyLower Price TargetOutperform$40.00 ➝ $33.00High
i
Rating by David Maris at Wells Fargo & Company
2/27/2019BTIG ResearchLower Price TargetBuy$35.00High
i
2/27/2019BMO Capital MarketsBoost Price TargetOutperform$40.00High
i
2/27/2019Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$33.00High
i
1/31/2019MizuhoReiterated RatingNeutralHigh
i
Rating by I. Koffler at Mizuho
1/23/2019UBS GroupDowngradeBuy ➝ Neutral$54.00 ➝ $32.00Medium
i
11/20/2018Cantor FitzgeraldReiterated RatingHold$41.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
11/15/2018ArgusUpgradeHold ➝ Buy$42.00Medium
i
11/6/2018JPMorgan Chase & Co.Set Price TargetBuy$45.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
11/6/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Buy$40.00High
i
Rating by David Maris at Wells Fargo & Company
11/6/2018Royal Bank of CanadaLower Price TargetOutperform ➝ Buy$51.00 ➝ $50.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
11/6/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Hold$36.00 ➝ $39.00High
i
Rating by David Risinger at Morgan Stanley
11/6/2018CitigroupLower Price TargetBuy ➝ Buy$48.00 ➝ $44.00High
i
11/6/2018CowenSet Price TargetHold$31.00High
i
Rating by Ken Cacciatore at Cowen Inc
11/6/2018Bank of AmericaUpgradeNeutral ➝ Buy$44.00 ➝ $42.00High
i
11/5/2018Cantor FitzgeraldReiterated RatingHold$41.00High
i
Rating by Louise Chen at Cantor Fitzgerald
10/9/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$46.00 ➝ $36.00Low
i
10/5/2018MizuhoDowngradeBuy ➝ NeutralLow
i
Rating by I. Koffler at Mizuho
8/24/2018Evercore ISIUpgradeIn-Line ➝ OutperformLow
i
8/15/2018Wells Fargo & CompanyReiterated RatingHoldLow
i
Rating by David Maris at Wells Fargo & Company
8/13/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$53.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
8/9/2018CitigroupLower Price TargetBuy ➝ Buy$50.00 ➝ $48.00High
i
8/9/2018SVB LeerinkLower Price TargetOutperform$53.00 ➝ $47.00High
i
Rating by A. Fadia at SVB Leerink LLC
8/9/2018Raymond JamesDowngradeStrong-Buy ➝ OutperformHigh
i
8/9/2018CowenReiterated RatingHold$31.00High
i
8/8/2018Cantor FitzgeraldReiterated RatingHold$41.00High
i
Rating by Louise Chen at Cantor Fitzgerald
8/8/2018Wells Fargo & CompanySet Price TargetHold$41.00High
i
Rating by David Maris at Wells Fargo & Company
8/8/2018MizuhoReiterated RatingBuy$54.00High
i
8/2/2018Wells Fargo & CompanyReiterated RatingHoldLow
i
Rating by David Maris at Wells Fargo & Company
7/25/2018Wells Fargo & CompanyReiterated RatingHoldMedium
i
Rating by David Maris at Wells Fargo & Company
6/29/2018Cantor FitzgeraldSet Price TargetHold$41.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
6/14/2018GuggenheimReiterated RatingBuy$59.00Medium
i
6/6/2018GuggenheimReiterated RatingBuy$59.00Medium
i
5/31/2018Wells Fargo & CompanySet Price TargetMarket Perform ➝ Hold$43.00 ➝ $41.00High
i
Rating by David Maris at Wells Fargo & Company
5/29/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$43.00 ➝ $42.00Medium
i
5/23/2018JPMorgan Chase & Co.Set Price TargetBuy$53.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
5/9/2018Cantor FitzgeraldSet Price TargetHold$41.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
4/23/2018Wells Fargo & CompanyReiterated RatingHoldLow
i
Rating by David Maris at Wells Fargo & Company
4/12/2018JPMorgan Chase & Co.Set Price TargetBuy$53.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
4/12/2018SVB LeerinkUpgradeMarket Perform ➝ Outperform$44.00Low
i
Rating by A. Fadia at SVB Leerink LLC
4/11/2018Cantor FitzgeraldSet Price TargetHold$41.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
4/9/2018Morgan StanleySet Price TargetBuy$50.00High
i
Rating by David Risinger at Morgan Stanley
4/3/2018Royal Bank of CanadaSet Price TargetHold$45.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
3/15/2018MizuhoBoost Price TargetBuy$45.00 ➝ $51.00Low
i
3/6/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$39.00 ➝ $50.00Medium
i
3/1/2018UBS GroupSet Price TargetBuy$54.00High
i
Rating by Marc Goodman at UBS Group AG
3/1/2018Cantor FitzgeraldSet Price TargetHold$41.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
2/16/2018JPMorgan Chase & Co.Set Price TargetBuy$53.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
1/25/2018140166Reiterated RatingPositive ➝ Positive$47.00 ➝ $55.00Low
i
1/24/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$50.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
1/18/2018Wells Fargo & CompanySet Price TargetHold$33.00 ➝ $43.00Low
i
1/11/2018The Goldman Sachs GroupBoost Price TargetBuy$46.00 ➝ $52.00High
i
1/4/2018CitigroupReiterated RatingBuy ➝ Buy$48.00 ➝ $58.00High
i
1/2/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$44.00Low
i
Rating by A. Fadia at SVB Leerink LLC
12/26/2017Cantor FitzgeraldSet Price TargetHold$41.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
12/12/2017GuggenheimInitiated CoverageBuy ➝ Buy$59.00Low
i
12/4/2017UBS GroupSet Price TargetBuy$46.00Low
i
Rating by Marc Goodman at UBS Group AG
11/30/2017Cantor FitzgeraldSet Price TargetHold$34.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
11/7/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $37.00N/A
i
10/31/2017Cantor FitzgeraldSet Price TargetHold$34.00N/A
i
10/24/2017MizuhoReiterated RatingBuy$37.00N/A
i
10/20/2017Royal Bank of CanadaSet Price TargetHold$32.00N/A
i
10/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$44.00 ➝ $48.00N/A
i
10/6/2017Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $39.00N/A
i
10/5/2017UBS GroupReiterated RatingBuy$46.00N/A
i
10/5/2017Nomura InstinetReiterated RatingBuy$37.00N/A
i
10/5/2017CowenReiterated RatingMarket Perform$30.00 ➝ $36.00N/A
i
10/4/2017CitigroupSet Price TargetBuy$42.00N/A
i
10/4/2017MizuhoReiterated RatingBuy$37.00N/A
i
10/4/2017Wells Fargo & CompanySet Price TargetHold$30.00 ➝ $32.00N/A
i
10/4/2017Cantor FitzgeraldReiterated RatingHold$34.00High
i
10/4/2017BTIG ResearchBoost Price TargetBuy ➝ Buy$42.00 ➝ $45.00High
i
9/29/2017BMO Capital MarketsReiterated RatingBuy$45.00Low
i
9/8/2017Cantor FitzgeraldReiterated RatingHold$34.00Low
i
8/22/2017ArgusDowngradeBuy ➝ Hold$47.59 ➝ $29.39Low
i
8/20/2017MizuhoReiterated RatingBuy$53.00 ➝ $37.00Low
i
8/16/2017CitigroupUpgradeNeutral ➝ Buy$36.00 ➝ $42.00Medium
i
8/10/2017UBS GroupReiterated RatingBuy$50.00 ➝ $46.00High
i
8/10/2017BMO Capital MarketsReiterated RatingOutperform$50.00 ➝ $45.00High
i
8/10/2017Royal Bank of CanadaReiterated RatingSector Perform$33.00 ➝ $32.00Low
i
8/9/2017CowenReiterated RatingHold$43.00 ➝ $30.00Medium
i
8/9/2017Cantor FitzgeraldSet Price TargetHold$34.00Medium
i
8/9/2017Wells Fargo & CompanySet Price TargetHold$34.50 ➝ $30.00Medium
i
8/7/2017Morgan StanleyLower Price TargetEqual ➝ Equal Weight$52.00 ➝ $36.00Medium
i
8/4/2017Royal Bank of CanadaReiterated RatingHold$41.00 ➝ $33.00High
i
8/3/2017CowenReiterated RatingHold$43.00High
i
7/16/2017Royal Bank of CanadaSet Price TargetHold$41.00Medium
i
6/16/2017Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$41.00Low
i
6/13/2017Royal Bank of CanadaReiterated RatingHold$41.00High
i
5/31/2017Wells Fargo & CompanyReiterated RatingMarket Perform$40.00Medium
i
5/22/2017BarclaysUpgradeEqual Weight ➝ Overweight$47.00 ➝ $50.00Low
i
5/21/2017CowenReiterated RatingMarket Perform$55.00 ➝ $43.00Medium
i
5/13/2017Royal Bank of CanadaSet Price TargetHold$41.00Low
i
5/11/2017Royal Bank of CanadaLower Price TargetSector Perform$39.00 ➝ $36.00Low
i
5/1/2017BMO Capital MarketsInitiated CoverageOutperform$50.00Low
i
4/18/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$52.00 ➝ $51.00Low
i
4/17/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$48.00 ➝ $46.00Low
i
4/14/2017Wells Fargo & CompanyReiterated RatingMarket Perform$40.00N/A
i
3/30/2017SVB LeerinkReiterated RatingOutperform$52.00Low
i
3/30/2017MizuhoReiterated RatingBuy$53.00Low
i
3/30/2017Royal Bank of CanadaReiterated RatingSector Perform$48.00Low
i
3/20/2017SVB LeerinkReiterated RatingOutperformLow
i
3/13/2017MizuhoBoost Price TargetBuy ➝ Buy$47.00 ➝ $53.00Low
i
3/11/2017BarclaysReiterated RatingEqual Weight$44.00 ➝ $47.00N/A
i
3/6/2017SVB LeerinkReiterated RatingOutperform$52.00N/A
i
3/3/2017GuggenheimReiterated RatingNeutralN/A
i
3/2/2017Royal Bank of CanadaSet Price TargetHold$44.00 ➝ $48.00N/A
i
2/28/2017MizuhoReiterated RatingBuy$47.00N/A
i
1/5/2017GuggenheimReiterated RatingNeutralN/A
i
1/5/2017CitigroupDowngradeBuy ➝ Neutral$59.00 ➝ $44.00N/A
i
1/3/2017BTIG ResearchReiterated RatingBuy$55.00N/A
i
12/30/2016Stifel NicolausReiterated RatingPositiveN/A
i
12/7/2016MizuhoReiterated RatingBuy$49.00 ➝ $47.00N/A
i
11/29/2016BTIG ResearchReiterated RatingBuy$55.00N/A
i
11/18/2016MizuhoLower Price TargetBuy$49.00 ➝ $47.00N/A
i
11/10/2016Royal Bank of CanadaReiterated RatingSector Perform$48.00 ➝ $44.00N/A
i
11/10/2016BarclaysReiterated RatingHold$44.00N/A
i
10/26/2016MizuhoInitiated CoverageBuy$49.00N/A
i
10/10/2016JPMorgan Chase & Co.Set Price TargetBuy$52.00N/A
i
10/10/2016BTIG ResearchReiterated RatingBuy$55.00N/A
i
10/10/2016Royal Bank of CanadaReiterated RatingSector Perform$48.00N/A
i
10/10/2016UBS GroupReiterated RatingBuy$66.00 ➝ $60.00N/A
i
10/10/2016Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$57.00N/A
i
10/10/2016UBS GroupUpgradeMarket Perform ➝ Strong-BuyN/A
i
10/4/2016JPMorgan Chase & Co.Set Price TargetBuy$52.00N/A
i
10/1/2016SVB LeerinkSet Price TargetBuy$55.00 ➝ $45.00N/A
i
10/1/2016Wells Fargo & CompanySet Price TargetHold$44.00N/A
i
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/A
i
9/23/2016Deutsche Bank AktiengesellschaftSet Price TargetBuy$60.00 ➝ $58.00N/A
i
9/22/2016SVB LeerinkReiterated RatingBuyN/A
i
9/22/2016ArgusSet Price TargetBuy$55.00N/A
i
9/6/2016Royal Bank of CanadaLower Price TargetSector Perform$52.00 ➝ $48.00N/A
i
9/4/2016Wells Fargo & CompanySet Price TargetHold$44.00N/A
i
8/30/2016BTIG ResearchReiterated RatingBuy$60.00N/A
i
8/30/2016SVB LeerinkReiterated RatingOutperform$55.00N/A
i
8/26/2016Evercore ISIReiterated RatingHold$49.00N/A
i
8/25/2016The Goldman Sachs GroupReiterated RatingConviction-Buy$60.00N/A
i
8/25/2016Wells Fargo & CompanyReiterated RatingMarket Perform$44.00N/A
i
8/24/2016Bank of AmericaReiterated RatingBuy$70.00N/A
i
8/15/2016SVB LeerinkBoost Price TargetOutperform$51.00 ➝ $55.00N/A
i
7/12/2016Morgan StanleyReiterated RatingHoldN/A
i
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
5/17/2016UBS GroupReiterated RatingBuy$66.00N/A
i
5/13/2016The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$60.00N/A
i
5/4/2016SVB LeerinkLower Price TargetOutperform$53.00 ➝ $51.00N/A
i
4/26/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
3/21/2016Wells Fargo & CompanyReiterated RatingMarket PerformN/A
i
3/8/2016BTIG ResearchReiterated RatingBuy$60.00N/A
i
2/19/2016ArgusLower Price TargetBuy$65.00 ➝ $55.00N/A
i
2/19/2016Wells Fargo & CompanyInitiated CoverageMarket PerformN/A
i
2/16/2016SVB LeerinkLower Price TargetOutperform$53.00 ➝ $50.00N/A
i
2/11/2016CitigroupReiterated RatingBuyN/A
i
2/11/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
2/11/2016GuggenheimReiterated RatingNeutralN/A
i
2/11/2016Royal Bank of CanadaReiterated RatingHold$60.00 ➝ $58.00N/A
i
2/11/2016CowenLower Price TargetMarket Perform$65.00 ➝ $55.00N/A
i
(Data available from 1/24/2016 forward)
Mylan logo
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Read More

Today's Range

Now: $15.86
$15.34
$16.15

50 Day Range

MA: $15.57
$14.37
$15.86

52 Week Range

Now: $15.86
$12.75
$23.11

Volume

14,100,488 shs

Average Volume

6,488,034 shs

Market Capitalization

$8.59 billion

P/E Ratio

29.92

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?

The following Wall Street research analysts have issued stock ratings on Mylan in the last year: Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, SunTrust Banks, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.

What is the current price target for Mylan?

6 Wall Street analysts have set twelve-month price targets for Mylan in the last year. Their average twelve-month price target is $20.33, suggesting a possible upside of 28.2%. SunTrust Banks, Inc. has the highest price target set, predicting MYL will reach $27.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $16.00 for Mylan in the next year.

What is the current consensus analyst rating for Mylan?

Mylan currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYL, but not buy more shares or sell existing shares.

What other companies compete with Mylan?

How do I contact Mylan's investor relations team?

Mylan's physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is 724-514-1800 and its investor relations email address is [email protected] The official website for Mylan is www.mylan.com.